| Literature DB >> 34686910 |
Florian Doldi1, Benedikt Biller2, Florian Reinke2, Lars Eckardt2.
Abstract
Leadless pacing systems, especially the Micra™ TPS system, deliver an effective and safe alternative to the previous conventional transvenous systems in patients with impossible transvenous access and seem to be compatible with other implantable devices (S-ICD, deep brain stimulators) with no limitations in efficacy or safety. Also, new outlooks on leadless resynchronization therapy seem promising and could prevent future patients from lead- or operation-associated complications. Current limits to the implementation in everyday clinical practice are mostly the unavailability of the devices or cost issues through lack of health insurance reimbursement. However, more promising data through further studies and rising implantation rates are expected based on the positive current clinical data.Entities:
Keywords: Arrhythmias, cardiac; Bradycardia; Defibrillator, subcutaneous; Heart failure; Resynchronization
Mesh:
Year: 2021 PMID: 34686910 DOI: 10.1007/s00059-021-05075-6
Source DB: PubMed Journal: Herz ISSN: 0340-9937 Impact factor: 1.443